

March 31, 2025

To Listing Department, <b>NATIONAL STOCK EXCHANGE OF INDIA LIMITED</b> Exchange Plaza, Bandra Kurla Complex, Bandra (E), <b>MUMBAI -400 051</b>  <b>Company Code No. AUROPHARMA</b>	To The Corporate Relations Department <b>BSE LIMITED</b> Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> floor, Dalal Street, <b>MUMBAI -400 001</b>  <b>Company Code No. 524804</b>
---	---

Dear Sir/ Madam,

**Sub: Cautionary Email received from the stock exchanges regarding delay in intimation of Schedule of Investors Meet**

**Ref: 1) Email dated March 28, 2025, received from NSE**

**2) Email No. LIST/COMP/JP/1772/2024-25 dated March 28, 2025, received from BSE**

**3) Our disclosure dated March 28, 2025, to the stock exchanges.**

We have disclosed the receipt of the above referred cautionary e-mails to the stock exchanges on March 28, 2025. We are submitting herewith the disclosure again in the prescribed format as **Annexure** to this letter.

Please take the above information on record.

Thanking you,

Yours faithfully,

**For AUROBINDO PHARMA LIMITED**

B. Adi Reddy  
Company Secretary

Encl: as above.

**AUROBINDO PHARMA LIMITED**

[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.  
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)

**Annexure**

S. No.	Particulars	Details
1	Name of the authority	National Stock Exchange of India Limited (NSE) and BSE Limited (BSE)
2	Nature and details of the action(s) taken, initiated or order(s) passed by the Authority	The Company has received cautionary emails from NSE and BSE regarding delay in intimation of Schedule of Investors meet held on June 10, 2024, in New York, USA. Due to time differences, there was a delay in confirmation of this overseas meeting schedule, hence, we could not disclose the schedule of the meeting within the requisite timelines to the stock exchanges.
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority.	Cautionary emails were received from NSE and BSE on March 28, 2025, regarding delay in intimation of Schedule of Investors Meet
4	Details of the violation(s)/contravention(s) committed or alleged to be committed	Delay in intimation of Schedule of Investors meet held on June 10, 2024
5	Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on the Company's financials or operations due to the said cautionary letters.

**AUROBINDO PHARMA LIMITED**
[www.aurobindo.com](http://www.aurobindo.com)

(CIN : L24239TG1986PLC015190)

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India.  
Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 Telangana., India Tel: +91 40 2373 6370 / 2374 7340 Fax: +91 40 2374 1080 / 2374 6833  
Email: [info@aurobindo.com](mailto:info@aurobindo.com) Website: [www.aurobindo.com](http://www.aurobindo.com)